Market overview
The global clinical trials market is worth USD 118 bn in 2026 and is forecast to reach USD 232 bn by 2036, growing at a 7.0% CAGR. United States is the largest country market and Phase 3 is the largest by phase segment.
| Scope | Total spending on conducting human clinical trials, including site and investigator fees, patient recruitment, central laboratories, clinical supplies, monitoring and trial technology. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 110 bn |
| Value 2026 | USD 118 bn |
| Value 2036 | USD 232 bn |
| CAGR 2026-2036 | 7.0% |
| Volume 2026 | 39,476 trials |
| Volume 2036 | 57,782 trials |
| Average price 2026 | USD 2,982,000 per trial |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Clinical Trials market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 118 bn |
| 2027 | USD 126 bn |
| 2028 | USD 135 bn |
| 2029 | USD 144 bn |
| 2030 | USD 154 bn |
| 2031 | USD 165 bn |
| 2032 | USD 177 bn |
| 2033 | USD 189 bn |
| 2034 | USD 202 bn |
| 2035 | USD 216 bn |
| 2036 | USD 232 bn |
Clinical Trials market segmentation
By phase
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Phase 1 | 12.0% | 11.4% | USD 14.1 bn | 6.5% |
| Phase 2 | 22.0% | 22.0% | USD 25.9 bn | 7.0% |
| Phase 3 | 50.0% | 49.9% | USD 58.9 bn | 7.0% |
| Phase 4 | 16.0% | 16.7% | USD 18.8 bn | 7.5% |
By therapy area
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oncology | 36.0% | 40.5% | USD 42.4 bn | 8.3% |
| Immunology and inflammation | 12.0% | 11.7% | USD 14.1 bn | 6.8% |
| Neurology | 11.0% | 10.3% | USD 12.9 bn | 6.3% |
| Cardiovascular and metabolic | 15.0% | 16.1% | USD 17.7 bn | 7.8% |
| Infectious disease | 8.0% | 6.2% | USD 9.4 bn | 4.3% |
| Other | 18.0% | 15.3% | USD 21.2 bn | 5.3% |
By sponsor
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pharmaceutical | 62.0% | 56.1% | USD 73.0 bn | 5.9% |
| Biotechnology | 34.0% | 40.6% | USD 40.0 bn | 8.9% |
| Academic and government | 4.0% | 3.3% | USD 4.7 bn | 4.9% |
By study design
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Interventional | 66.0% | 64.0% | USD 77.7 bn | 6.7% |
| Observational | 18.0% | 18.0% | USD 21.2 bn | 7.0% |
| Expanded access and registry | 16.0% | 18.0% | USD 18.8 bn | 8.3% |
By service
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Study management | 40.0% | 38.0% | USD 47.1 bn | 6.5% |
| Patient recruitment | 18.0% | 20.0% | USD 21.2 bn | 8.1% |
| Data management | 22.0% | 22.0% | USD 25.9 bn | 7.0% |
| Site services | 20.0% | 20.0% | USD 23.5 bn | 7.0% |
Top 25 countries for clinical trials by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 80.5% of 2026 revenue and the 25 countries below together hold 94.5%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 44.7 bn | 38.0% | USD 82.7 bn | 6.3% |
| 2 | China | USD 14.1 bn | 12.0% | USD 36.1 bn | 9.8% |
| 3 | Germany | USD 5.9 bn | 5.0% | USD 10.9 bn | 6.3% |
| 4 | United Kingdom | USD 5.3 bn | 4.5% | USD 9.7 bn | 6.3% |
| 5 | France | USD 4.7 bn | 4.0% | USD 8.8 bn | 6.5% |
| 6 | Japan | USD 4.7 bn | 4.0% | USD 8.8 bn | 6.5% |
| 7 | Spain | USD 4.1 bn | 3.5% | USD 7.6 bn | 6.4% |
| 8 | Italy | USD 4.1 bn | 3.5% | USD 7.6 bn | 6.4% |
| 9 | Canada | USD 3.5 bn | 3.0% | USD 6.5 bn | 6.3% |
| 10 | South Korea | USD 3.5 bn | 3.0% | USD 8.3 bn | 9.0% |
| 11 | Poland | USD 2.3 bn | 1.9% | USD 4.7 bn | 7.5% |
| 12 | Australia | USD 2.2 bn | 1.9% | USD 4.1 bn | 6.3% |
| 13 | India | USD 1.8 bn | 1.6% | USD 3.8 bn | 7.5% |
| 14 | Brazil | USD 1.7 bn | 1.5% | USD 3.6 bn | 7.6% |
| 15 | Netherlands | USD 1.4 bn | 1.2% | USD 2.6 bn | 6.3% |
| 16 | Belgium | USD 1.3 bn | 1.1% | USD 2.4 bn | 6.3% |
| 17 | Switzerland | USD 1.0 bn | 0.9% | USD 1.9 bn | 6.4% |
| 18 | Russia | USD 859 mn | 0.7% | USD 1.8 bn | 7.6% |
| 19 | Israel | USD 836 mn | 0.7% | USD 1.6 bn | 6.4% |
| 20 | Mexico | USD 812 mn | 0.7% | USD 1.7 bn | 7.5% |
| 21 | Taiwan | USD 600 mn | 0.5% | USD 1.3 bn | 7.6% |
| 22 | Turkey | USD 483 mn | 0.4% | USD 996 mn | 7.5% |
| 23 | Sweden | USD 424 mn | 0.4% | USD 764 mn | 6.1% |
| 24 | Austria | USD 365 mn | 0.3% | USD 671 mn | 6.3% |
| 25 | Saudi Arabia | USD 318 mn | 0.3% | USD 648 mn | 7.4% |
| Rest of world | USD 6.4 bn | 5.5% | USD 12.0 bn | 6.4% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- IQVIA
- Thermo Fisher Scientific (PPD)
- ICON
- Parexel
- Syneos Health
- Fortrea
Group 2: Regional and specialist players
- Medpace
- Charles River Laboratories
- WuXi AppTec
- Tigermed
- Veeva Systems
- Medidata
- Novotech
- Labcorp Drug Development
- PSI CRO
- Precision for Medicine
Group 3: Emerging and niche players
- Clario
- Signant Health
- Science 37
- Advarra
- WCG Clinical
- Greenphire
- Suvoda
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the clinical trials market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 7.0% is calculated from the resulting values.
The market is divided by phase, by therapy area, by sponsor, by study design, by service. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the clinical trials market?
The global clinical trials market is estimated at USD 110 bn in 2025 and USD 118 bn in 2026.
How fast will the clinical trials market grow?
It is forecast to reach USD 232 bn by 2036, a compound annual growth rate of 7.0% from 2026, an increase of USD 114 bn.
Which country is the largest market for clinical trials?
United States is the largest market by revenue at USD 44.7 bn in 2026, 38.0% of the global total. The three largest countries together hold 55.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 9.8% a year from 2026 to 2036.
Which clinical trials segment is largest?
In the by phase split, Phase 3 is the largest segment with 50.0% of 2026 revenue.
Who are the leading clinical trials companies?
Global leaders include IQVIA, Thermo Fisher Scientific (PPD), ICON, Parexel.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Peptide TherapeuticsUSD 110 bn · 12.0% CAGR
- In Vitro DiagnosticsUSD 108 bn · 5.5% CAGR
- TelemedicineUSD 103 bn · 13.0% CAGR
- Contract Development and Manufacturing OrganizationUSD 140 bn · 8.0% CAGR
- Diabetes DrugsUSD 97.5 bn · 5.0% CAGR
- Generic InjectableUSD 93.3 bn · 6.3% CAGR
- Contract Research OrganizationUSD 91.8 bn · 8.0% CAGR
- Cardiovascular DevicesUSD 83.8 bn · 7.0% CAGR